Last ¥2,391 JPY
Change Today +5.00 / 0.21%
Volume 95.9K
4569 On Other Exchanges
Symbol
Exchange
Tokyo
OTC US
As of 1:00 AM 01/29/15 All times are local (Market data is delayed by at least 15 minutes).

kyorin holdings inc (4569) Snapshot

Open
¥2,373
Previous Close
¥2,386
Day High
¥2,408
Day Low
¥2,363
52 Week High
09/25/14 - ¥2,452
52 Week Low
05/9/14 - ¥1,830
Market Cap
179.2B
Average Volume 10 Days
156.1K
EPS TTM
¥148.87
Shares Outstanding
74.9M
EX-Date
03/27/15
P/E TM
16.1x
Dividend
¥52.00
Dividend Yield
2.59%
Current Stock Chart for KYORIN HOLDINGS INC (4569)

Related News

No related news articles were found.

kyorin holdings inc (4569) Related Businessweek News

No Related Businessweek News Found

kyorin holdings inc (4569) Details

KYORIN Holdings, Inc., through its subsidiaries, researches and develops, produces, and sells ethical, generic, over-the-counter drugs, and others in Japan and internationally. The company operates in two segments, Pharmaceutical Business and Consumer Healthcare (Skincare) Business. Its products primarily include Flutiform, a drug for the treatment of asthma; Uritos, which is a therapeutic agent for overactive bladder; Kipres for the treatment of bronchial asthma and allergic rhinitis; Pentasa for the treatment of ulcerative colitis and Crohn’s disease; and Mucodyne, a mucoregulan drug. The company also offers Milton, a baby bottle disinfectant; Rubysta, a disinfectant cleaner; skincare and cosmetic products based on nanocapsule technology, a pharmaceutical formulation concept; and prescription medicines and quasi-drugs, diagnostics, and industrial chemicals. In addition, it is involved in the discovery and evaluation of candidate compounds; and research and analysis of other companies’ technologies and collection of information concerning clinical trials. Further, the company’s pipeline products include KRP-AB1102 and KRP-AB1102F for the treatment of chronic obstructive pulmonary disease that are under Phase III clinical development; KRP-AM1977X for the treatment of infectious diseases that is under Phase II clinical development; and KRP-114V and KRP-EPA605 for overactive bladder. Additionally, it pipeline products comprise KRP-209 for Tinnitus; KRP-203 for transplantation, autoimmune diseases, and IBD; KRP-AM1977X, an oral antibacterial agent; and KRP-AM1977Y, an injection. The company’s other pipeline products include Ad-SGE-REIC formulation, a gene-therapy product; and Dimethyl sulfoxide for the treatment of interstitial cystitis. KYORIN Holdings, Inc. was founded in 1923 and is headquartered in Tokyo, Japan.

2,452 Employees
Last Reported Date: 06/25/14
Founded in 1923

kyorin holdings inc (4569) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

kyorin holdings inc (4569) Key Developments

KYORIN Holdings, Inc. Reports Consolidated Financial Results for the Six Months Ended September 30, 2014; Provides Earnings and Dividend Guidance for the Full Year Ending March 31, 2015; Announces Dividend for the Second Quarter Ended September 30, 2014, Payable on December 5, 2014

KYORIN Holdings, Inc. reported consolidated earnings results for the six months ended September 30, 2014. For the six months, the company reported operating income of ¥4,587 million and net income of ¥3,495 million or ¥46.78 per basic share on net sales of ¥51,112 million against operating income of ¥6,213 million, and net income of ¥4,397 million or ¥58.85 per basic share on net sales of ¥50,851 million for the same period of last year. Ordinary income was ¥4,898 million against ¥6,531 million a year ago. For the full year ending March 31, 2015, the company expects ordinary income of ¥13,800 million, operating income of ¥13,800 million, and net income of ¥11,600 million or ¥155.26 per share on net sales of ¥111,700 million. The company announced a dividend of ¥20 per share for the second quarter ended September 30, 2014. Scheduled date for starting dividend payment is December 5, 2014. The company expects to pay dividend of ¥32 per share for the year ending March 31, 2015.

KYORIN Holdings, Inc., Q2 2015 Earnings Call, Nov 05, 2014

KYORIN Holdings, Inc., Q2 2015 Earnings Call, Nov 05, 2014

KYORIN Holdings, Inc. to Report Q2, 2015 Results on Nov 04, 2014

KYORIN Holdings, Inc. announced that they will report Q2, 2015 results on Nov 04, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4569:JP ¥2,391.00 JPY +5.00

4569 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4569.
View Industry Companies
 

Industry Analysis

4569

Industry Average

Valuation 4569 Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KYORIN HOLDINGS INC, please visit www.kyorin-gr.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.